When Zheng Xiaoyu took the helm of the Chinese State Food and Drug Administration (SFDA) nine years ago, hopes were high for effective regulatory oversight of China's drug industry. Now those hopes have been dashed with tragic personal consequences for Zheng and allegations of widespread corruption by Chinese officials.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Web links
China State Food and Drug Administration
Rights and permissions
About this article
Cite this article
Jia, H. China syndrome—a regulatory framework in meltdown?. Nat Biotechnol 25, 835–837 (2007). https://doi.org/10.1038/nbt0807-835
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0807-835
- Springer Nature America, Inc.
This article is cited by
-
Backlog cripples China's drug regulator
Nature Biotechnology (2015)
-
Chinese health biotech and the billion-patient market
Nature Biotechnology (2008)
-
Chinese manufacturers vie for piece of outsourcing pie
Nature Biotechnology (2007)